Bionote Targets Annual Revenue of About KRW 300 Billion by FY2030

• Bionote's Oct. 22, 2026, value-up plan targets fiscal 2030 revenue of about KRW 300 billion.
• Targets also include a 30% operating margin and a price-to-book ratio of 1.2 times.
• Growth plans include expanding diagnostic platforms, increasing US subsidiary sales and establishing local production capacity.
• The strategy also calls for entering the antibody therapeutics market and expanding the life sciences business.
• Shareholder returns include maintaining stable dividends, with cancellation of 500,000 treasury shares annually under consideration for three years starting in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionote Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022800687), on October 22, 2026, and is solely responsible for the information contained therein.